American Society of HematologyTisagenlecleucel vs. SOC as 2L Therapy of Primary R/R Aggressive B-Cell NHL: Analysis of the Phase III Belinda Study

Adults with confirmed R/R aNHL within 12 months after first-line (1L) chemo-immunotherapy were eligible for the randomized Phase III study, which demonstrated that tisagenlecleucel (tisa-cel) as second-line (2L) treatment in R/R aNHL patients did not have a higher event-free survival (EFS) vs. the standard-of-care (SOC). Read this late-breaking abstract from the ASH Annual Meeting & […]

Millennium Medical PublishingEvolving Strategies for the Management of Transformed Lymphoma

Clinical Advances in Hematology & Oncology talks with Sonali M. Smith, MD, an Elwood V. Jensen Professor in Medicine and Chief, Section of Hematology/Oncology at the University of Chicago, about all things transformed lymphoma, including risk factors, distinguishing characteristics, pathogenesis, traditional treatment approaches, treatment goals, new treatment strategies, and other promising areas of research.

American Society of HematologyClonal Hematopoiesis in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Source: Blood AdvancesKey Points: In a cohort of 154 patients with NHL or MM receiving CAR T-cells, clonal hematopoiesis of indeterminate potential (CHIP) was present in 48%. Although associated with worse prognosis in these patients receiving autologous transplantation, no such association was seen in these patients receiving CAR T. Instead, the authors saw increased rates […]

American Society of Clinical OncologyLong-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

In this Original Report from the Journal of Clinical Oncology, the authors conducted a phase I trial of autologous CD19 CAR T cells in children and young adults (CAYAs) with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) to discover whether the role for allogeneic hematopoietic stem-cell transplant (alloHSCT) following CD19-CAR T-cell therapy can improve […]

Caribou PublishingASCO 2020: May 31 Highlights

Day two of ASCO 2020 featured late-breaking data from a phase 3 trial evaluating early local therapy in metastatic breast cancer, as well as results of the phase 3 ENDURANCE trial, the ALPHA CAR T-cell trial, and the C-144-01 trial assessing TIL therapy.